NeuraLace offers Axon Therapy®, a 100% non-invasive magnetic Peripheral Nerve Stimulation (mPNS) device designed to treat chronic neuropathic pain without the need for needles or surgical interventions. This technology provides significant pain reduction, minimizing reliance on opioids and improving patient quality of life through targeted neuromodulation.
Funding
$15.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic neuropathic pain is commonly treated with medications, including opioids, or invasive procedures, which may lead to adverse side effects, addiction, or surgical complications. Existing neuromodulation techniques often require injections, implants, or ablations, posing risks of infection and therapeutic interruptions.
Solution
NeuraLace offers Axon Therapy, a non-invasive magnetic Peripheral Nerve Stimulation (mPNS) device designed for treating chronic neuropathic pain. The device delivers high-intensity magnetic pulses at skin level to recondition the central nervous system by eliminating noxious pain signals. This approach provides a pain-free alternative to traditional methods, minimizing the need for opioids and other medications while improving patient quality of life. The mPNS mechanism of action is FDA-cleared for post-surgery and post-trauma neuromodulation.
Target Audience
The primary audience includes patients suffering from chronic neuropathic pain, as well as healthcare providers seeking non-invasive alternatives to traditional pain management methods.
Features
- 100% non-invasive neuromodulation without needles, scalpels, or implants
- High-intensity magnetic field administered at or above skin level
- Reconditions the central nervous system by eliminating noxious pain signals
- Spot treatments with an average of 60% pain reduction after complete treatment protocol (respondent patients only, VA Augusta Clinical Equipment Evaluation (CEC))
- FDA-cleared for post-surgery and post-trauma neuromodulation